171 related articles for article (PubMed ID: 26033177)
21. Phase II study of oral topotecan in advanced non-small cell lung cancer.
White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Palackdharry CS
Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Han JY; Lee DH; Kim HY; Hong EK; Yoon SM; Chun JH; Lee HG; Lee SY; Shin EH; Lee JS
Cancer; 2003 Nov; 98(9):1918-24. PubMed ID: 14584075
[TBL] [Abstract][Full Text] [Related]
24. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
[TBL] [Abstract][Full Text] [Related]
25. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
26. Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients.
Garg P; Rana F; Gupta R; Buzaianu EM; Guthrie TH
Breast J; 2009; 15(4):404-8. PubMed ID: 19508671
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.
Igawa S; Yamamoto N; Ueda S; Ono A; Nakamura Y; Tsuya A; Murakami H; Endo M; Takahashi T
J Thorac Oncol; 2007 Aug; 2(8):741-4. PubMed ID: 17762341
[TBL] [Abstract][Full Text] [Related]
28. [Impact of early lymphopenia on the risk of febrile neutropenia and hematological toxicity].
Ben Nasr S; Zriba S; Kacem K; Yahyaoui Y; El Benna H; Mansouri R; Ben Lakhal R; Meddeb B
Tunis Med; 2015 May; 93(5):283-6. PubMed ID: 26578043
[TBL] [Abstract][Full Text] [Related]
29. [Cancer treatment in elderly patients: evidence and clinical research].
Repetto L; Luciani A
Recenti Prog Med; 2015 Jan; 106(1):23-7. PubMed ID: 25621776
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
[TBL] [Abstract][Full Text] [Related]
31. Impact of group psychotherapy in chemotherapy induced vomiting for treatment of advanced breast and lungs cancer.
Parvez T; Alharbi TM; Mein FD
J Coll Physicians Surg Pak; 2007 Feb; 17(2):89-93. PubMed ID: 17288854
[TBL] [Abstract][Full Text] [Related]
32. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
33. Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study.
Ostwal V; Ramaswamy A; Bhargava P; Hatkhambkar T; Swami R; Rastogi S; Mandavkar S; Ghosh J; Bajpai J; Gulia S; Srinivas S; Rath S; Gupta S
BMJ Open; 2021 Jun; 11(6):e047376. PubMed ID: 34187825
[TBL] [Abstract][Full Text] [Related]
34. Functional decline in older patients with cancer receiving first-line chemotherapy.
Hoppe S; Rainfray M; Fonck M; Hoppenreys L; Blanc JF; Ceccaldi J; Mertens C; Blanc-Bisson C; Imbert Y; Cany L; Vogt L; Dauba J; Houédé N; Bellera CA; Floquet A; Fabry MN; Ravaud A; Chakiba C; Mathoulin-Pélissier S; Soubeyran P
J Clin Oncol; 2013 Nov; 31(31):3877-82. PubMed ID: 24062399
[TBL] [Abstract][Full Text] [Related]
35. Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy.
do Nascimento TG; de Andrade M; de Oliveira RA; de Almeida AM; Gozzo Tde O
Rev Lat Am Enfermagem; 2014; 22(2):301-8. PubMed ID: 26107839
[TBL] [Abstract][Full Text] [Related]
36. Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement.
Moth EB; Kiely BE; Stefanic N; Naganathan V; Martin A; Grimison P; Stockler MR; Beale P; Blinman P
J Geriatr Oncol; 2019 Mar; 10(2):202-209. PubMed ID: 30224184
[TBL] [Abstract][Full Text] [Related]
37. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Muss HB; Berry DA; Cirrincione C; Budman DR; Henderson IC; Citron ML; Norton L; Winer EP; Hudis CA;
J Clin Oncol; 2007 Aug; 25(24):3699-704. PubMed ID: 17704418
[TBL] [Abstract][Full Text] [Related]
38. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience.
De Maio E; Gravina A; Pacilio C; Amabile G; Labonia V; Landi G; Nuzzo F; Rossi E; D'Aiuto G; Capasso I; Rinaldo M; Morrica B; Elmo M; Di Maio M; Perrone F; de Matteis A
BMC Cancer; 2005 Mar; 5():30. PubMed ID: 15790416
[TBL] [Abstract][Full Text] [Related]
39. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
40. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]